Hepatic hormone FGF21 and its analogues in clinical trials

• 作者: Shao Weijuan Jin Tianru
• 来源期刊: 慢性疾病与转化医学（英文）
• 关键词: dual agonists fibroblast growth factor 21 lipid metabolism metabolic diseases
• 年，卷（期）: 2022,（1）
• 所属期刊栏目: Review
• 页码范围: 19-25
• 页数: 7页
• 语种: 中文
• DOI: 10.1016/j.cdtm.2021.08.005

摘要

Fibroblast growth factor 21 (FGF21) is a fasting or stress inducible metabolic hormone produced mainly in the liver. It plays important roles in regulating both glucose and lipid homeostasis via interacting with a heterodimeric receptor complex comprising FGF receptor 1 (FGFR1) and β-klotho (KLB). For the past decade, great effort has been made on developing FGF21 derivatives or specific FGF21 receptor agonists into therapeutic agents for various metabolic disorders including type 2 diabetes (T2D), obesity, and more importantly, nonalcoholic fatty liver disease (NAFLD). Here we have reviewed FGF21 gene and protein structures, its expression pattern, cellular signaling cascades that mediate FGF21 production and function. We have then summarized the six clinical trials utilizing four FGF21 analogues. Finally, two recent literatures on the development of GLP-1 and FGF21 dual agonists were presented briefly.